Sparing in Neuromuscular Blockade in COVID 19 ICU

CompletedOBSERVATIONAL
Enrollment

250

Participants

Timeline

Start Date

June 1, 2020

Primary Completion Date

June 1, 2020

Study Completion Date

June 1, 2020

Conditions
Neuromuscular BlockadeHuman CharacteristicsComplication of Medical CareIntensive Care Unit Acquired Weakness
Interventions
DEVICE

TOF protocol

"To the introduction of CISATRACURIUM, Initial bolus was at 0.2mg/kg and initial continuous infusion at 0.18mg/kg/h of theoretical ideal weight.~To the introduction of ATRACURIUM, initial bolus was at 0.5mg/kg and initial continuous infusion at 0.5mg/kg/h of theoretical ideal weight.~Introduction of NMBA was associated to deep sedation (RASS - 4 or RAMSAY 6; BIS 40 to 60).~TOF was measured through the electric stimulation of peripheral nerves (facial or ulnar nerve).~The dose of NMB agents was then adapted according to the number of answers to the TOF, per 4 hours:~* If 0 response and no respiratory asynchrony: no change in flow rate~* If \>=1 or respiratory asynchrony: increase of the continuous curare flow by 20% preceded by a bolus identical to the one administered at the beginning of NMB agent, then recheck at H+1."

Trial Locations (1)

69004

Department of Anesthesiology and Intensive Care Medicine, Hôpital de la Croix Rousse, Hospices Civils de Lyon, Lyon

All Listed Sponsors
lead

Hospices Civils de Lyon

OTHER

NCT04459533 - Sparing in Neuromuscular Blockade in COVID 19 ICU | Biotech Hunter | Biotech Hunter